このページの翻訳は実験的なもので、現在開発中です。お待ちしております

IRRAS 将来の成長

Future 基準チェック /26

IRRASは、38.8%と63%でそれぞれ年率38.8%で利益と収益が成長すると予測される一方、EPSはdeclineで104.4%年率。

主要情報

38.8%

収益成長率

-104.4%

EPS成長率

Medical Equipment 収益成長	27.1%
収益成長率	63.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	24 Jul 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

OM:IRRAS - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	320	N/A	N/A	N/A	1
12/31/2024	195	-108	-141	-127	1
12/31/2023	116	-150	-170	-162	2
6/30/2023	43	-196	-195	-192	N/A
3/31/2023	43	-193	-197	-193	N/A
12/31/2022	40	-167	-179	-176	N/A
9/30/2022	37	-164	-160	-157	N/A
6/30/2022	32	-141	-133	-129	N/A
3/31/2022	27	-131	-134	-129	N/A
12/31/2021	22	-136	-138	-131	N/A
9/30/2021	18	-131	-131	-123	N/A
6/30/2021	14	-135	-134	-125	N/A
3/31/2021	10	-140	-139	-129	N/A
12/31/2020	7	-136	-141	-133	N/A
9/30/2020	8	-134	-151	-144	N/A
6/30/2020	7	-139	-159	-152	N/A
3/31/2020	7	-147	-166	-152	N/A
12/31/2019	5	-151	-169	-154	N/A
9/30/2019	2	-165	-159	-138	N/A
6/30/2019	1	-171	-146	-125	N/A
3/31/2019	0	-160	-130	-116	N/A
12/31/2018	6	-139	-112	-97	N/A
9/30/2018	7	-112	-103	-95	N/A
6/30/2018	18	-78	-90	-82	N/A
3/31/2018	18	-67	-78	-68	N/A
12/31/2017	12	-61	-65	-54	N/A
9/30/2017	11	-48	-53	-35	N/A
12/31/2016	N/A	-32	N/A	-18	N/A
12/31/2015	N/A	-13	N/A	-11	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IRRAS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IRRAS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IRRAS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IRRASの収益 ( 63% ) Swedish市場 ( 1.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: IRRASの収益 ( 63% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IRRASの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

IRRAS 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

Price target increased by 69% to kr5.00

Consensus revenue estimates decrease by 25%

Price target increased to kr5.00

IRRAS AB Provides Revenue Guidance for the Year 2022

Price target decreased to kr7.00

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00

New 90-day high: kr6.98

Analysts increase revenue estimates to kr27.5m

First half earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘